A recent study published in The Lancet Oncology found that children with intracranial ependymoma can avoid the damaging effects of radiotherapy by receiving chemotherapy treatment instead. In a study of 89 children, 42% avoided radiotherapy and had better overall survival rates.
A recent meta-analysis confirms that combining trastuzumab with chemotherapy reduces mortality by -34% and increases disease-free survival by 38% in women with operable HER-2 positive breast cancer. This treatment strategy also decreases the risk of locoregional and distant recurrences.
Researchers have developed a new tool that uses patient characteristics such as age, gender, race, and tumor site to estimate conditional survival. This will enable personalized predictions of prognosis for head and neck cancer patients.
Researchers found that unrelated umbilical cord blood transplants can provide similar five-year survival rates to allele-matched bone marrow transplants for children with acute leukemia. However, matched cord blood transplants showed greater survival rates but required further study to confirm.
A review of nine randomized trials shows that patients treated with cisplatin lived slightly longer than those treated with carboplatin, with a median survival of 9.1 months compared to 8.4 months. However, the difference in survival was not statistically significant for all patient groups.
The Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial demonstrated Nexavar's effectiveness in extending overall survival by 44% compared to placebo. Hepatocellular carcinoma is the most common form of liver cancer, responsible for about 90% of primary malignant liver tumors in adults.
A new treatment, Sorafenib, has been shown to increase overall survival by over 40% in patients with advanced liver cancer. The study, SHARP, involved 602 patients and found that Sorafenib delays tumor progression and improves survival.
Researchers found a widening disparity in life expectancy between white and black women with advanced breast cancer, with median survival rates differing by up to 8.8% over the last two decades. Socio-economic factors, such as access to healthcare and treatment options, are suspected to be contributing factors.
A recent study found that antidepressant sertraline does not improve symptoms or survival in advanced cancer patients without major depression. The researchers concluded that the overmedicalisation of these patients should be avoided, and treatment with sertraline should be reserved for cases with a proven indication.
A multicenter Phase II study of enzastaurin as a second- or third-line treatment for NSCLC found a median progression-free survival of 1.9 months and an overall survival rate of 46.3% at 12 months. The most common toxicity was fatigue.
A study of 519 patients found no benefit in overall survival from pre-operative chemotherapy for nonsmall cell lung cancer. Neo-adjuvant therapy did result in tumor down-staging and improved response rates, but its use should be targeted towards specific patient subgroups.
Researchers have developed protocols to maximize post-release survival of commonly caught species, including luderick and Murray cod. Key recommendations include cutting lines on fish that swallow hooks, resulting in improved mortality rates for some species.
The Novo-TTF device has been shown to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off. In a pilot trial, 10 patients with recurring GBM experienced improved survival rates, with median overall survival doubling compared to historical data.
A study of HCV patients post-liver transplantation reveals stagnant survival rates, contrasting with improving outcomes for non-HCV recipients. Researchers analyzed a large sample of US liver transplant data between 1991 and 2001, finding HCV patients had lower 3-year survival rates and no improvement in survival over time.
A study published in JAMA Network found that levosimendan did not improve survival rates for patients with decompensated heart failure compared to dobutamine. The researchers analyzed data from 1,327 patients who received either intravenous levosimendan or dobutamine and found no significant difference in long-term survival outcomes.
A meta-analysis of studies found that controlling for socioeconomic factors reduced racial disparities in colorectal cancer survival. Lower socioeconomic status is linked to poorer health outcomes and reduced access to healthcare.
A randomized controlled trial of high-risk gastric cancer patients showed no significant difference in survival between two treatment groups. The five-year survival rate was around 50%, higher than previous studies, suggesting that the quality of surgery and potential toxicity of postoperative chemotherapy may be factors.
A phase III trial of 1,298 patients found that a combination of cetuximab and irinotecan increased progression-free survival over irinotecan alone. The treatment also showed a higher tumor response rate.
Researchers found that cetuximab improved overall survival by 23% and reduced disease progression risk by 32%. The drug targets the EGFR receptor on cancer cells, preventing cell growth and triggering an immune response.
Early-stage breast cancer patients who receive a single method of treatment, such as tamoxifen or chemotherapy, have improved survival rates. Chemotherapy shows modest yet sustained benefits in relapse-free and overall survival, particularly in younger women and those without ovarian suppression.
According to a randomized controlled trial, radiation therapy is the preferred treatment option for patients with locally advanced stage IIIA-N2 non-small-cell lung cancer who have responded to chemotherapy. This finding suggests that surgery may not improve survival rates compared to radiation after chemotherapy treatment.
A new study found that routine colonoscopic surveillance improves survival for colorectal cancer patients. Patients who underwent regular follow-up colonoscopies had better five-year survival rates compared to those who did not receive screenings.
A new analysis confirms the benefit of switching treatment from tamoxifen to an aromatase inhibitor on disease-free survival, with a modest improvement in overall survival for oestrogen-receptor-positive patients. The findings suggest that molecular markers may predict which patients benefit from endocrine treatment strategy.
A new study reveals that breast cancer patients taking tamoxifen who switch to an aromatase inhibitor within three years experience significant improvements in survival rates. The treatment demonstrates a clear survival benefit without an increased risk of death from other causes.
Giving women with HER2-receptor positive breast cancer Herceptin for one year after standard chemotherapy improves their survival. The study found a significant overall survival benefit in the drug group compared to the control group.
Teens with cancer face poor survival rates due to limited clinical trial participation, lack of awareness about their risk, and delayed diagnoses. The 15-29 age group has seen no improvement in survival rates over the past 25 years.
A new study demonstrates the effectiveness of Pfizer's Aromasin for early breast cancer treatment, with improved relapse-free survival and disease-free survival rates. The B-33 trial found that Aromasin was well-tolerated and showed a significant improvement in patients who received it after five years of tamoxifen.
A new study found a significant improvement in survival rates after stroke in Auckland, New Zealand, with a 40% decline in deaths over the past 25 years. The research attributes this increase to better hospital admission and brain imaging during the most severe phase of the illness.
A recent study published in The Lancet Oncology found that switching to anastrozole after 2-3 years of tamoxifen treatment significantly improves overall survival and reduces the risk of recurrence for postmenopausal women with hormone-sensitive early-stage breast cancer. The study analyzed data from three trials and used meta-analysis...
A study of 5,820 Japanese-American men found that avoiding health risks like smoking and obesity can lead to a longer and healthier life. The researchers identified several risk factors associated with healthy survival, including high grip strength, physical fitness, and avoiding excessive drinking.
A study found that adding radiation therapy after prostate gland removal reduced PSA relapse and disease recurrence risk by 50% and 38%, respectively. However, it did not improve overall survival or metastasis-free survival.
A large-scale study involving over 7,500 men with prostate cancer has concluded that a rise in PSA levels after treatment, known as PSA bounce, does not impact overall survival. The study found no statistical difference in survival rates between patients who experienced a bounce and those who did not.
The study found that men with aggressive locally advanced prostate cancer who received additional hormones lived longer, with a 31.9% increase in survival compared to those without further hormone therapy. The benefits also extended to men with less aggressive cancers, with improved disease-free and disease-specific survival rates.
Researchers developed a new model to predict survival after liver transplantation, considering specific characteristics of donors and recipients. The model identified key factors impacting graft survival, including donor age and recipient MELD score.
A study by the NIH/National Institute on Aging demonstrates that resveratrol, an activator of sirtuins, can improve health and survival in aged overweight male mice. Resveratrol supplementation improved insulin sensitivity, reduced liver size, and enhanced motor function in the mice compared to those without resveratrol.
Adult heart transplant recipients who received HCV-positive donor hearts had higher mortality rates and lower survival rates at 1, 5, and 10 years. The study suggests that transplanting hearts from donors with hepatitis C should be avoided if possible.
A study found that less than one-third of gastric cancer patients had adequate lymph node assessments, leading to compromised survival. Median survival in regions with the highest ALNA rate was 33 months, while in regions with the lowest rate it was only 17 months.
A study found that directly observed therapy and physician experience positively influenced TB patient survival in Toronto over three years. Physician training and experience also played a significant role in managing TB cases effectively.
A new biomarker predicting survival in colorectal carcinomas has been discovered, with thymidylate synthase levels in the nucleus and cytoplasm identified as critical markers. The ratio of nuclear to cytoplasmic TS levels also predicts decreased survival, revealing a new potential biomarker for patients with worse prognosis.
A study published in the American Cancer Society found that women with higher levels of physical activity before diagnosis had better five-year survival patterns compared to those with lower activity levels.
A new treatment combining high-dose radiotherapy after surgery and short-term intense chemotherapy improves the overall five-year survival rate of children with medulloblastoma to 85% for average-risk patients. High-risk patients see a significant increase in survival rates, from 55% to 70%, while reducing side effects.
A phase III study found that adding topotecan to standard chemotherapy for ovarian cancer does not increase overall survival or reduce cancer recurrence. The treatment instead leads to more blood-related toxicities and infections.
Researchers found that combining chemotherapy with radiation therapy after surgery significantly improves survival rates for patients with advanced pancreatic cancer. The study showed a median survival time of 18.3 months, compared to the national average of 11 months.
A study shows that a prostate cancer vaccine, sipuleucel-T, can increase survival by up to four-and-a-half months and provide a greater than three-fold increase in survival at 36 months compared to patients in the placebo group. The vaccine was well-tolerated with mild adverse effects.
Researchers reviewed data from 156 patients with inflammatory breast cancer and found that a standard combination of therapies did not significantly increase survival rates. The study highlights the need for further research to identify subsets of patients who may benefit from alternative treatment approaches.
A multicenter study found no significant difference in survival rates between automated LDB-CPR and manual CPR after out-of-hospital cardiac arrest. However, another study showed improved outcomes with the use of an automated device, including higher survival rates to hospital discharge.
Researchers De Paepe and Taddei found that bacteriophages exhibit life history trade-offs between survival and reproduction, with rapid reproducers suffering higher casualties outside the host. Two physical parameters account for most of the observed variation in survival, suggesting a fundamental property of evolving entities.
A study comparing Japanese American and white male patients who received hormone treatment for prostate cancer found that the former had a significantly higher five-year overall survival rate of 66% compared to 42%. The result was not affected by cancer stage or PSA levels, suggesting genetic and lifestyle factors may play a role.
A new study reveals that post-operative radiation therapy improves overall survival in select lung cancer patients whose disease has spread to regional lymph nodes. This is the first significant increase in survival rate since previous studies used outdated equipment.
Researchers report improved survival rates with RP101, a novel compound being investigated as a potential therapeutic for advanced pancreatic cancer. In two studies, patients showed significant improvements in median survival and time to progression, offering hope for patients affected by the disease.
Researchers at OHSU Cancer Institute analyzed data from 5,587 colon cancer subjects to determine five-year conditional survival rates. The study found that as time elapsed since diagnosis, most subjects experienced an improvement in their subsequent five-year conditional survival following the initial disease-free period.
A study by OHSU Cancer Institute physicians validates the reclassification of breast cancer stages, improving disease-free survival rates for patients previously diagnosed with Stage II and III. The revised classification system has been shown to increase 10-year survival rates for these patients, from 30-36%.
A new combination therapy after surgery has improved survival rates for pancreatic cancer patients by 50%, increasing median survival from 16.9 to 20.6 months. The study found significant benefits for patients with pancreatic head adenocarcinoma, a type of cancer that affects the pancreas.
A new three-drug regimen combining Taxotere with standard chemotherapy reduces mortality by nearly 30 percent in patients with squamous cell carcinoma of the head and neck. The study, conducted at Dana-Farber Cancer Institute, showed improved survival rates with this treatment approach.
Early breast cancer patients switching from tamoxifen to Aromasin experience a 17% lower chance of dying and a 25% lower risk of breast cancer recurrence. The study's findings also suggest long-term safety benefits, with no clinically meaningful changes in the side effect profile.
Researchers at UC Davis Cancer Center report a significant extension of survival in advanced lung cancer patients treated with bortezomib plus standard care. The median overall survival was 11 months, with one-year survival at 46%, offering promising results for this patient population.
Male guppies with rare color patterns have a highly significant survival advantage in the wild, surviving at 84% rate compared to 69% for common-patterned males. This phenomenon is linked to frequency-dependent survival, where rarity confers an advantage over common variants.
PET scans can accurately predict prognosis and five-year survival rates in cervical cancer patients. Tumors with high glucose uptake have lower survival rates and disease-free survival rates.
A study by U-M researchers found that patients with delayed surgery (more than 93 days) had worse survival rates and lower three-year survival rates compared to those with timely surgery. Scheduling issues were the most common cause of delay, which can lead to micrometastases and poor outcomes.
Patients undergoing more extensive (D3) lymph node dissection had higher 5-year overall survival rates compared to those with less extensive (D1) surgery. D3 nodal dissection offers a survival benefit when performed by experienced surgeons.